Russian registry of resistant arterial hypertension (REGATTA): study design
- Авторлар: Chazova IE1, Fomin VV1, Razuvaeva MA1, Vigdorchik AV1, Chazova IE1, Fomin VV1, Razuvaeva MA1, Vigdorchik AV1
-
Мекемелер:
- Шығарылым: № 2 (2009)
- Беттер: 52-54
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245824
- ID: 245824
Дәйексөз келтіру
Толық мәтін
Аннотация
Негізгі сөздер
Авторлар туралы
I Chazova
V Fomin
M Razuvaeva
A Vigdorchik
I Chazova
V Fomin
M Razuvaeva
A Vigdorchik
Әдебиет тізімі
- Российское Медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.
- Cushman WC, Ford CE, Cutler JA, et al. for the ALLHAT Collaboratyive Research Group. Success and predictors of blood pressure control in diverse North American Settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
- Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18(5 Pt. 1):619-26.
- Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens 2001;14(12):1263-69.
- Чазова И.Е., Фомин В.В. Резистентная артериальная гипертензия // Терапевтический архив. 2008. № 6. С. 72-79.
- Sloand JA, Balakroshnan SL, Fong MW, et al. Evaluation and treatment of resistant hypertension. Cardiology J 2007;14(4):329-39.
- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation and teratment: A scientific statement form the American Heart Association professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
- Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15(4 Pt. 1):333-39.
- Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49(4):839-45.
- Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003;21(11):2149-57.
- Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the insidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-42.
- Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol 2009;62(2):158-66.
- Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press 2009;18(1):74-77.
- Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
- Alleman Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: the Exforge in Failure after Single Therapy (Ex-FAST) Study. J Clin Hypertens (Greenwich) 2008;10(3):185-94.